Evidence map›Paper›PMID 41668983›Full record

ArticleJournal of biomedical physics & engineering2026

Selenium-Curcumin-PEG Nanoparticles Radiosensitization for Intensity-Modulated Radiation Therapy of Lung Tumor Cells:

Farid Mortazavi, Paria Tamaddon, Ali Ketabi, Hanieh Haghighi, Kiana Khajeheian, Masoud Haghani, Tahereh Mahmoudi, Sadegh Masjoodi, Masoud Negahdary, Naghmeh Sattarahmady

Abstract read
In one paragraph

Article in Journal of biomedical physics & engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Farid MortazaviNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Paria TamaddonDepartment of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali KetabiNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hanieh HaghighiNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Kiana KhajeheianDepartment of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Masoud HaghaniNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Tahereh MahmoudiNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sadegh MasjoodiNeuroscience Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran.
Masoud NegahdaryDepartment of Biomedical Engineering, Texas A&M University, 600 Discovery Drive, College Station, TX, 77840-3006, USA.
Naghmeh SattarahmadyNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer is a leading cause of cancer-related mortality worldwide, underscoring the need for the development of more effective treatment strategies. Radiotherapy (RT), particularly intensity-modulated radiation therapy (IMRT), has enhanced tumor targeting while minimizing damage to healthy tissues. Nevertheless, radioresistance and challenges posed by the tumor microenvironment limit its efficacy. Objective: Selenium-curcumin-polyethylene glycol 600 nanoparticles (Se-Cur-PEG NPs) analyzed as radiosensitizers in IMRT for lung cancer treatment. Material and Methods: In this experimental study, Se-Cur-PEG NPs were synthesized and characterized for their potential as radiosensitizers. Results: The Conclusion: These findings suggest that Se-Cur-PEG NPs hold promise as effective radiosensitizers, potentially improving lung cancer RT outcomes.

Indexed as

Intensity-ModulatedLung NeoplasmsOxidative StressRadiation-Sensitizing AgentsSelenium nanoparticles

Identifiers

PMID41668983
PMCPMC12883924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.